

Figure S4




Figure S4. A, Flow cytometry dot plots showing in vitro phagocytosis of ZL-1201 in combination with trastuzumab with or without Fc γ R blockade on HCC1954 cells. B. Flow cytometry dot plots showing in vitro phagocytosis of ZL-1201 in combination with rituximab-IgG1 or rituximab –(Fab')₂ on Toledo cells. D-G. In vitro phagocytosis of HCC1954 (D), SKOV3 (E), FaDu (F), or Toledo (G) treated with isotype or benchmark in combination with trastuzumab (D and E), cetuximab (F) or rituximab (G) (0.1 μ g/mL) with or without Fc γ R blockade. H, I. In vitro phagocytosis of SKOV3 (H) and Cal27 (I) treated with isotype control (NT), ZL-1201 in combination with trastuzumab-IgG1 or trastuzumab –F(ab')₂ (H); or cetuximab-IgG1 or cetuximab –F(ab')₂ (I). Data shown as mean \pm SD, *p<0.05, **p<0.01.